JP2021504329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504329A5 JP2021504329A5 JP2020528072A JP2020528072A JP2021504329A5 JP 2021504329 A5 JP2021504329 A5 JP 2021504329A5 JP 2020528072 A JP2020528072 A JP 2020528072A JP 2020528072 A JP2020528072 A JP 2020528072A JP 2021504329 A5 JP2021504329 A5 JP 2021504329A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- optionally
- subject
- immune checkpoint
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590785P | 2017-11-27 | 2017-11-27 | |
| US62/590,785 | 2017-11-27 | ||
| US201862635958P | 2018-02-27 | 2018-02-27 | |
| US62/635,958 | 2018-02-27 | ||
| PCT/US2018/062621 WO2019104327A1 (en) | 2017-11-27 | 2018-11-27 | Gp96-based cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504329A JP2021504329A (ja) | 2021-02-15 |
| JP2021504329A5 true JP2021504329A5 (https=) | 2022-01-06 |
Family
ID=66631729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528072A Pending JP2021504329A (ja) | 2017-11-27 | 2018-11-27 | Ｇｐ９６ベースの癌療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210170025A1 (https=) |
| EP (1) | EP3717003A4 (https=) |
| JP (1) | JP2021504329A (https=) |
| KR (1) | KR20200092964A (https=) |
| CN (1) | CN111405909A (https=) |
| AU (1) | AU2018373390A1 (https=) |
| CA (1) | CA3083481A1 (https=) |
| WO (1) | WO2019104327A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
| AU2020395765A1 (en) | 2019-12-03 | 2022-06-16 | Neuvogen, Inc. | Tumor cell vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110017356A (ko) * | 2008-03-20 | 2011-02-21 | 유니버시티 오브 마이애미 | 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법 |
| BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
| EP3288982A1 (en) * | 2015-04-28 | 2018-03-07 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
-
2018
- 2018-11-27 AU AU2018373390A patent/AU2018373390A1/en not_active Abandoned
- 2018-11-27 US US16/763,867 patent/US20210170025A1/en not_active Abandoned
- 2018-11-27 CA CA3083481A patent/CA3083481A1/en active Pending
- 2018-11-27 EP EP18881711.8A patent/EP3717003A4/en not_active Withdrawn
- 2018-11-27 JP JP2020528072A patent/JP2021504329A/ja active Pending
- 2018-11-27 CN CN201880076245.9A patent/CN111405909A/zh active Pending
- 2018-11-27 WO PCT/US2018/062621 patent/WO2019104327A1/en not_active Ceased
- 2018-11-27 KR KR1020207015128A patent/KR20200092964A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Advances in cancer immunotherapy: historical perspectives, current developments, and future directions | |
| Gupta et al. | Immunotherapy: an alternative promising therapeutic approach against cancers | |
| Zhu et al. | The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond | |
| Martin-Liberal et al. | The expanding role of immunotherapy | |
| Zhang et al. | Current status and future directions of cancer immunotherapy | |
| Bernstein et al. | Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions | |
| Ventola | Cancer immunotherapy, part 1: current strategies and agents | |
| McCracken et al. | Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don't eat me” signals | |
| Tongu et al. | Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo | |
| JP2020508329A5 (https=) | ||
| JP2019501670A5 (https=) | ||
| Wang et al. | Radiotherapy as a new player in immuno-oncology | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| Desbaillets et al. | Immunotherapy in glioblastoma: a clinical perspective | |
| Kim | Immune checkpoint blockade therapy for bladder cancer treatment | |
| Liu et al. | Immune-based therapy clinical trials in hepatocellular carcinoma | |
| Xu et al. | Enhanced cellular therapy: revolutionizing adoptive cellular therapy | |
| Rafii et al. | Advancing CAR T-cell therapy in solid tumors: current landscape and future directions | |
| Murphy | Trends in cancer immunotherapy | |
| Rafiq et al. | Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects | |
| Thomas | Dendritic cells as targets or therapeutics in rheumatic autoimmune disease | |
| JP2021504329A5 (https=) | ||
| Sun et al. | Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges | |
| Yan et al. | OX40 as a novel target for the reversal of immune escape in colorectal cancer | |
| Mandala et al. | Rationale for new checkpoint inhibitor combinations in melanoma therapy |